News
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment.
The National Weather Service issued a report at 9:14 p.m. EDT on Tuesday for strong thunderstorms until 10 p.m. EDT for St.
The upcoming spin-off of The Handmaid's Tale, The Testaments, hasn't confirmed Elisabeth Moss's return as June, but she ...
The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...
This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...
Gilead Sciences Inc. closed 9.97% short of its 52-week high of $119.96, which the company reached on March 10th.
Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...
A man who could be facing the death penalty in the death of a Morrow County sheriff’s deputy had his second arraignment ...
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a significant setback after the US Food and Drug Administration put on hold ...
Gilead is laying off 36 people as part of a rethink that saw the Big Pharma scrap plans to expand a biologics facility in ...
Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results